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Evolution of a Revolution*Paul Sorajja, MD, Wesley Pedersen, MDSEE PAGE 1339T ranscatheter aortic valve replacement(TAVR) is a revolutionary therapy that hashad a profound impact not only on the care
of patients with aortic stenosis but also on the
entire cardiovascular profession. To date, more than
100,000 patients worldwide have received this life-
saving therapy. With continued population aging,
the prevalence of candidates is expected to further
increase (1). With its demonstrated efﬁcacy in im-
proving survival and quality of life, TAVR is now
endorsed in U.S. and European practice guidelines
for the treatment of symptomatic patients with
severe aortic stenosis who are either inoperable or
at high surgical risk (2,3). Now that the transfor-
mative beneﬁts of TAVR are established, the remain-
ing questions are focused on further improvements
in the technology and its potential application in
a broader population, including lower-risk patients.
Current TAVR therapy has its challenges. Even
though procedural success rates for TAVR exceed
90%, the inability to retrieve and redeploy existing
prostheses can lead to misplacement and complica-
tions such as aortic regurgitation, coronary occlusion,
and device embolization, occasionally leading to
emergency surgery. With high surgical risk or inop-
erable status established as an indication for TAVR,
emergency surgery in these patients is considerably
perilous and may be prohibitive. The irreversible
nature of deployment with current TAVR prostheses
therefore mandates an extraordinarily high level of*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Center for Valve and Structural Heart Disease, Minneapolis
Heart Institute at Abbott Northwestern Hospital, Minneapolis,
Minnesota. Both authors have reported that they have no relationships
relevant to the contents of this paper to disclose.training and expertise, usually facilitated by intense
proctoring and a continued need for multiple physi-
cian operators to work cohesively to perform the
procedure. Other concerns with TAVR include the
need to demonstrate prosthesis durability and to
further reduce the incidence of stroke, pacemaker
dependency, vascular injury, and signiﬁcant residual
paravalvular regurgitation. Certainly, randomized
trials and post-market registries have demonstrated
that high levels of clinical efﬁcacy can be achieved
through systematic education and the use of dedi-
cated, specialized healthcare teams (4). Nonetheless,
these challenges remain and are relevant because
complications of almost any degree in these pro-
cedures can lead to poorer survival given the high-risk
aspects of these patients and their relative fragility.The report of the REPRISE II (REpositionable
Percutaneous Replacement of Stenotic Aortic Valve
Through Implantation of Lotus Valve System: Evalu-
ation of Safety and Performance) registry by Meredith
et al. (5) in this issue of the Journal highlights several
innovations in TAVR therapy that help to address some
present-day challenges. The Lotus valve (Boston Sci-
entiﬁc Corp., Marlborough, Massachusetts) is a bovine
pericardial, mechanically expanded, nitinol prosthesis
with an adaptive seal to help prevent paravalvular
regurgitation, deliverable with an 18-F (23-mm valve)
or 20-F (27-mm valve) system. The valve leaﬂets are
fully functional early during deployment (w50%
of unsheathing), thereby allowing slow, deliberate
placement without the need for rapid ventricular
pacing. The most intriguing feature of the Lotus valve
is its ability to be fully recaptured after deployment
and before release. The Lotus valve can thus be
repositioned in the event of device malposition or an
untoward complication (e.g., coronary occlusion).
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of 120 patients treated with the Lotus valve, deploy-
ment occurred successfully in 100% of patients
without a single case of device migration, emboliza-
tion, need for valve-in-valve therapy, or emergency
cardiac surgery. The lone procedural death was due to
cardiac perforation. Partial or complete retrieval was
used during deployment in 32 patients (26.7%), and
this ability certainly was a major factor in the
remarkable procedural success reported in this study.
The primary device performance endpoint of the
study was mean aortic valve gradient at the 30-day
follow-up, assessed by an independent echocardio-
graphic core laboratory. The REPRISE II registry dem-
onstrates the efﬁcacy of Lotus valve implantation for
the relief of aortic stenosis: the mean aortic gradient
was reduced from 46  15 mm Hg to 11  5 mm Hg
(p < 0.001), in association with an increase in
the effective oriﬁce area from 0.67  0.21 cm2 to 1.67 
0.43 cm2 (p < 0.001). Post-implant paravalvular
regurgitation also was much lower than reported in
previous TAVR studies. There were no incidences of
severe regurgitation; only 1 patient had moderate
regurgitation, and 84% had no or trace regurgitation.
This improvement could have been due, in part, to
protocol-mandated use of computed tomographic im-
aging for annular sizing but is also likely attributable to
the adaptive seal technology of the prosthesis, hoop
strength, and its ability to be repositioned. The data on
the Lotus valve meet or exceed the hemodynamic
performance of other currently available TAVR pros-
theses, although it is important to note that echocar-
diograms were not evaluable for the aortic gradient in
19.2% of patients, nor for the valve area in 35% of the
cohort. Incomplete echocardiographic data are hardly
unique to this study; for example, 8% of the patients in
the U.S. CoreValve High-Risk Study and 13% of those in
the PARTNER (Placement of AoRtic TraNscathetER
Valves) A study did not have 30-day data on mean
gradient or aortic valve area (6,7). However, a higher
rate of follow-up for such data might have been
expected for REPRISE II, because hemodynamic
assessment of the valve prosthesis was the primary
endpoint of the study. Certainly, clinical outcomes and
comparative data on safety and efﬁcacy are of para-
mount concern in these studies, and the upcoming
pivotal, randomized REPRISE III trial will enable ana-
lyses on the performance of the Lotus valve compared
with other commercially available prostheses.
The REPRISE II data suggest that TAVR can
be performed with a high rate of implantation
success using a therapy that, absent certain potential
complications (e.g., vascular injury, stroke), is revers-
ible if not believed to be effective. A small-proﬁlereversible prosthesis for TAVR therapy, with a seal
for prevention of paravalvular regurgitation, is the
emerging hallmark of next-generation devices, with
other examples such as Portico (St. Jude Medical,
St. Paul, Minnesota) and Direct Flow Medical (Direct
Flow Medical Inc., Santa Rosa, California). These
innovations and their association with favorable out-
comes can engender discussion regarding the expan-
sion of TAVR indications to a broader, lower-risk
patient population. Although the precision of the So-
ciety of Thoracic Surgeons risk calculator does have
limitations, recent data suggest that TAVR already is
being used in patients who are at less surgical risk
than those who were enrolled in the trials used for
commercial approval (4,6–9). Of note, the mean Soci-
ety of Thoracic Surgeons risk score for the patients in
the recent report of the post-market TVT Registry was
w7% (similar to both REPRISE II and U.S. CoreValve
High-risk studies), but it was w11% in the PARTNER I
studies. The PARTNER 2, SAPIEN 3, and SURTAVI
(Surgical Replacement and Transcatheter Aortic Valve
Implantation) studies are all evaluating TAVR in
intermediate-risk patients. The emerging availability
of completely retrievable prostheses, such as the
Lotus valve, will only serve to embolden discussion
for expanded indications, even in patients at lower
risk of open surgery.
Nonetheless, deployment success does not equate
to clinical success, and the availability of a therapeutic
option, by itself, is not justiﬁcation for its expanded
use. Concerns regarding stroke have plagued TAVR,
and stroke occurred in 5.9% of patients in REPRISE II
(disabling stroke in 1.7%). This observation could
be attributable to the small sample size, although
theoretically, an increased risk of stroke could arise
from excessive manipulation of the aortic valve
during device retrieval, and this should be addressed
with further study. Although there was a signiﬁcant
gradient reduction in REPRISE II, the investigators
also reported that the post-procedural indexed effec-
tive oriﬁce area was >0.85 cm2/m2 (or >0.70 cm2/m2
if body mass index was $30 kg/m2) in only 60.7%
of patients. Because of the ﬂow-dependent nature of
gradients and the relation between oriﬁce area and
long-term outcomes after aortic valve replacement, an
integrated approach is recommended for the assess-
ment of prosthetic valve stenosis, with the Valve Ac-
ademic Research Consortium (VARC)-2 criteria for
successful relief being a peak velocity <3 m/s or mean
gradient <20 mm Hg and an effective oriﬁce area >1.1
cm2 or indexed oriﬁce area >0.85 cm2/m2 for patients
with body mass index <30 kg/m2 (10).
Finally, a new permanent pacemaker was required
in 28.6% of patients. Implant depth has been shown
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patients, and the rate in REPRISE II occurred despite
the ability to reposition the valve higher in the left
ventricular outﬂow tract, if necessary (11). Approxi-
mately half of the pacemaker-dependent patients
(56%) were those with left ventricular outﬂow tracts
that were overstretched $10%, and thus, this prob-
lem may be addressed with the availability of more
prosthesis sizes (i.e., only the 23- and 27-mm sizes
were available in REPRISE II). Although studies thus
far have not suggested that pacemaker dependency
after TAVR affects survival, the effect of pacemaker
dependency may vary according to ventricular
function. In a recent study of 1,552 patients under-
going TAVR, new pacemaker dependency was asso-
ciated with worse left ventricular ejection fraction at
6 to 12 months follow-up (12). These data in TAVR
patients are consistent with well-studied effects of
dyssynchrony on ventricular function in patients
with other forms of systolic heart failure and could
become more relevant if data continue to demon-
strate different rates of pacemaker dependency for
the available TAVR prostheses.
The Lotus valve is emblematic of the ongoing
technological innovation in TAVR and is a harbingerof next-generation therapy in this ﬁeld. The high
deployment success and the low rate of complica-
tions (except for pacemaker dependency) in the
REPRISE II study are indeed remarkable. Of note, the
outcomes of TAVR with next-generation devices
should be considered in the context of outcomes with
open surgery, which represents the gold standard
and the results of which are beneﬁting from the heart
team approach in TAVR centers and continuing to
improve. Currently, there are w400 centers focused
on delivering TAVR to high-risk patients. Could an
easy-to-use, reversible technology such as that
demonstrated in REPRISE II lead to more centers and
relatively less experienced operators performing
TAVR, even for patients who are not at high surgical
risk? It certainly could, but only if the clinical out-
comes from expanded studies justify the indications
to do so.
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